Status:
WITHDRAWN
MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii
Lead Sponsor:
Institut Bergonié
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Thyroid carcinoma on struma ovarii (TCSO) is a rare ovarian tumor, derivate from monodermic teratomas. It represents about 0.01% of overall ovarian tumours, and 5 to 10% of struma ovarii. The diagnosi...
Detailed Description
This is a retrospective cohort with collection of tissues samples (FFPE or frozen), including female patients \>18-year-old treated in French between 2009 and 2016 for a thyroid carcinoma on struma ov...
Eligibility Criteria
Inclusion
- Alive patients,
- Age \> 18 years,
- Treatment in France for a TCSO, proven by an histologic diagnosis and registered in the " rare malignant gynecologic tumors " network.
Exclusion
- \- Patient lost to follow up.
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04053114
Start Date
January 1 2019
End Date
December 1 2020
Last Update
August 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Bergonié
Bordeaux, Aquitaine, France, 33076